News | Heart Failure | November 02, 2018

Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement

Controlled study of BVA-100 blood volume analyzer showed 86 percent reduction in one-year mortality

Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement

November 2, 2018 — In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the BVA-100 blood volume analyzer showed statistically significantly reduced 30-day readmission and 30-day and one-year mortality rates. The study, published in the Journal of the American College of Cardiology - Heart Failure,1 compared the experimental group to propensity-matched controls.

Treatment guided by the BVA-100 blood volume analyzer resulted in a statistically significant decrease in rehospitalization (12.2 percent vs. 27.7 percent, p<0.001), 30-day mortality (2 percent vs. 11.1 percent, p<0.001) and 365-day mortality (4.9 percent vs. 35.5. percent, p<0.001), compared to a propensity score control. Further, an analysis of 30-day readmission by diagnosis showed fewer heart failure readmissions (6.1 percent vs. 20.2 percent, p<0.001) and fewer cardiac non-heart failure admissions (1.6 percent vs. 3.9 percent, p<0.001).

"The results of this outcome study demonstrate without question that accurate blood volume measurement substantially improves the physician’s ability to prescribe decongestion therapy that will result in significantly better outcomes in acute heart failure, particularly with regard to rehospitalization and mortality,” said John E. Strobeck, M.D., Ph.D., director, Heart-Lung Consultants Inc., Hawthorne, N.J., and lead author of the study. “These results clearly show that BVA measurement has a one-to-one relationship in achieving meaningful improvements in clinical and resource-use outcomes in patients hospitalized for acute heart failure.”

Total blood volume, red blood cell volume and plasma volume were measured using Daxor’s BVA-100, an I-131 labeled albumin indicator dilution technique that is unique to the BVA-100. Patients were assigned a decongestion and treatment strategy based on the BVA-100 measurement. Propensity score control matching was derived from CMS data matching 10:1 for demographics, comorbidity and year of treatment.

Read the article Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

For more information: www.heartfailure.onlinejacc.org

Reference

1. Strobeck J.E., Feldschuh J., Miller W.L. Heart Failure Outcomes With Volume-Guided Management. JACC: Heart Failure, Nov. 1, 2018. DOI: 10.1016/j.jchf.2018.06.017


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now